Immunocore

Abingdon, United Kingdom Founded: 2008 • Age: 18 yrs Listed
Developer of drugs based on T-Cell receptor technology for the treatment of cancer

About Immunocore

Immunocore is a publicly listed company based in Abingdon (United Kingdom) founded in 2008 by Nicholas John Cross and George Kelly Martin. Developer of drugs based on T-Cell receptor technology for the treatment of cancer. Immunocore has raised $601.28 million across 9 funding rounds from investors including Lilly, WuXi AppTec and BlackRock. The company has 493 employees. Immunocore was last valued at $777.28 million in July 2015. Its website immunocore.com draws about 12 thousand monthly visits. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is IMMUNOCORE LIMITED. Its competitors include Autolus, Achilles Therapeutics and LIfT Biosciences; 3 of its 3 listed competitors have raised funding.

Company details

Immunocore was founded in 2008 in Abingdon, United Kingdom, within the biotechnology sector focused on oncology. Proprietary ImmTAC molecules are developed to mobilize the immune system against cancer cells by targeting peptide-HLA complexes and triggering T-cell responses via anti-CD3 fragments. Operations center on advancing bi-specific immunotherapeutics, with the lead candidate IMCgp100 directed toward uveal melanoma treatment.

  • Headquarters Abingdon, United Kingdom
  • Employees 493
  • Founders Nicholas John Cross, George Kelly Martin
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website immunocore.com
  • Social LinkedIn X YouTube
  • Legal Name Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh
Operational Areas
Key Metrics
  • Annual Revenue
    $400.95 M (USD)
    29.2
    as on Dec 31, 2025
  • Net Profit
    -$35.6 M (USD)
    30.35
    as on Dec 31, 2025
  • EBITDA
    -$42.19 M (USD)
    36.36
    as on Dec 31, 2025
  • Total Equity Funding
    $601.28M (USD)

    in 9 rounds

  • Latest Funding Round
    $140M (USD), Post-IPO

    Jul 2022

  • Investors
    Lilly

    & 12 more

  • Employee Count
    493

Apps and channels of Immunocore

its YouTube channel Immunocore has 156 subscribers and 16 videos.

Immunocore
YouTube 156 subscribers 16 videos Science & Technology
Open channel

Videos from Immunocore

The most watched videos on Immunocore's YouTube channel, Immunocore (156 subscribers). Click a video to play it here.

ImmTAC molecules: a closer look
2.5K views
Unlocking your superpower to fight diseases
1.3K views
How do ImmTAX molecules work?
770 views
HIV/AIDS: from discovery to the search for a functional cure
676 views

More on Immunocore.

Funding Insights of Immunocore

Immunocore has successfully raised a total of $601.28M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $140 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $601.28M
  • Total Rounds 9
  • Last Round Post-IPO β€” $140M
  • First Round $37.78M

    (Sep 2008)

  • Investors Count 13

All 9 funding rounds of Immunocore with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2022$140MPost-IPO––
–
Feb 2021$15MPost-IPO––
–
Jan 2021$100MDebt – Conventional––
Jan 2021$75MSeries C–BlackRock
–
Mar 2020$38.5MSeries B––
–
Apr 2019$130MSeries B–General Atlantic
Sep 2017$40MGrant––
Jul 2015$320MSeries B$777.28MMalin PLC, Woodford Investment Management
Sep 2008$37.78MSeries A––
–
Valuation history
DateValuationStage
Jul 2015$777.28Mβ€’β€’β€’β€’β€’β€’β€’β€’

Last known valuation $777.28M (Jul 2015). 13 investors in total: 13 institutional.

Investors in Immunocore

Immunocore has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, WuXi AppTec and BlackRock.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture debt firm focused on the life sciences sector
2002oxfordfinance.comAlexandria, United States
Private equity fund focused on global markets
1980generalatlantic.comNew York, United States
Companies developing T1D products are funded through venture philanthropy.
t1dfund.orgBoston, United States
Early-stage and late-stage biotech and finance companies are funded.
rockspringscapital.comBaltimore, United States
Private equity investments in China are managed by TMCP.
terramagnumcap.comChaoyang, China
Life Sciences focused VC firm investing in the US
2010rtwfunds.comNew York, United States
Diversified investment management firm and private fund focused on debt, equity, and secondary market investments in multiple sectors
1988blackrock.comNew York, United States
CCB International is engaged in investment banking and financial services.
ccbintl.com.hkHong Kong, Hong Kong
Traditional pharmaceutical medicines are developed for multiple health fields.
1876lilly.comUnited States
Provider of CRO and CDMO services
2000wuxiapptec.comShanghai, China
Premium access

Investor details for Immunocore

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Immunocore

62 people are tracked at Immunocore (41 in leadership, 6 in board & advisors, 15 in team); the tracked headcount is 493.

NameRoleGroup
Nicholas John Cross
Co-FounderLeadership
George Kelly Martin
Co-FounderLeadership
Lily Margaret Hepworth
Executive DirectorLeadership
Valerie Reynaert
Vice President Global Clinical OperationsLeadership
Debra Nielsen
Chief of StaffLeadership
Tina St. Leger
Chief Human Resources OfficerLeadership
Koustubh Ranade
SVP & Head Of Translational MedicineLeadership
Ralph Torbay
Chief Commercial Officer (cco)Leadership
Andrew Hooker
Senior Vice President, CMC & Supply Chain (immunocore Leadership Team)Leadership
Christina Sheil M.D.
VP Of PharmacovigilanceLeadership
Chris Conner
Senior Director, Oncology Account ManagementLeadership
Daniel Sum
Head, PharmacovigilanceLeadership
Kelly M. Armillotti
Director, Commercial Operations & Sales Force EffectivenessLeadership
Joann Suzich
Head of ResearchLeadership
Matt Newall
Director Global ProcurementLeadership
Bahija Jallal
Chief Executive OfficerLeadership
Mohammed Dar
Chief Medical Officer And Head Of Clinical DevelopmentLeadership
Annelise Vuidepot
CTO - Head Of Pipeline & Platform Research And UK Site HeadLeadership
David Berman
Head of Research and DevelopmentLeadership
Mark Moyer
Senior Vice President -regulatory, Pv, Quality Assurance Departments, And Project Lead Kimmtrak At ILeadership

42 more people are available in the full profile.

Premium access

Complete people profiles for Immunocore

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Immunocore

Immunocore is a publicly listed company on the NASDAQ with ticker symbol IMCR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date05 Feb 2021
  • Listed onNASDAQ: IMCR
  • Listed entityImmunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh
  • Exchange sectorHealth technology
  • ISINUS45258D1054
  • Share price$27.82 (-4.2% on the day) · 2026-10-13
  • Market capitalisation$1.43B
  • EPS (diluted, trailing year)$-0.35
  • Volume (last session)904,557

Financials of Immunocore

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$400.9M-$35.6M-$42.2M
2024$310.3M-$51.1M-$66.3M
2023$250.4M-$55.5M-$55.8M
2022$177.1M-$50.8M-$56.4M
2021$36.5M-$180.9M-$177.0M
Premium access

Detailed financial statements for Immunocore

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Immunocore

5 dated milestones of Immunocore across 14 years, from founding to its latest funding, stage changes and deals.

  1. Founded Immunocore is founded.
  2. Funding First funding round of $37.8M.
  3. Milestone Reaches Minicorn status.
  4. IPO Lists on the stock exchange (IPO).
  5. Funding Latest funding round, Post-IPO, of $140.0M.

Competitors of Immunocore

Immunocore has 3 listed competitors in our database, 3 of them funded. They include Autolus, Achilles Therapeutics and LIfT Biosciences.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
autolus.com2015London, United Kingdom$181.37M51
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
achillestx.com2016London, United Kingdom$241.98M118
T-cell therapies targeting tumor neo-antigens for cancer are developed.
liftbiosciences.com2016London, United Kingdom$20.13M8
Neutrophil-based cell therapies for solid tumors are developed.
Premium access

Detailed competitors of Immunocore

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Immunocore

The website of Immunocore (immunocore.com) receives about 11.9K visits a month and ranks #2,192,904 among all websites worldwide, #2,972 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    11.9K

    ▲ 8.8% vs previous month

  • Unique visitors
    4.3K

    per month

  • Global rank
    #2,192,904

    among all websites

  • Category rank
    #2,972

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Immunocore. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
cytomx.com
100%
17.7K#2,633,987View details
curevac.com
100%
21.2K#1,260,361View details
pmlive.com
96%
#627,237View details
pharmaphorum.com
96%
128.2K#451,885View details
qbiotics.com
67%
2.3K#7,924,987View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 7 similar websites and full traffic analytics for Immunocore

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 7 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Immunocore

Premium access

Complete news archive for Immunocore

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Immunocore

Immunocore was founded in 2008.

Immunocore is headquartered in Abingdon, United Kingdom. It is registered at Abingdon, Oxfordshire, United Kingdom.

Immunocore is a funded company, having raised a total of $601.28M across 9 funding rounds to date. The company's 1st funding round was a Series A of $37.78M, raised on Sep 2008.

Immunocore has 493 employees.

Annual revenue of Immunocore is $400.95M as on Dec 31, 2025.

Immunocore was founded in 2008 in Abingdon, United Kingdom, within the biotechnology sector focused on oncology. Proprietary ImmTAC molecules are developed to mobilize the immune system against cancer cells by targeting peptide-HLA complexes and triggering T-cell responses via anti-CD3 fragments. Operations center on advancing bi-specific immunotherapeutics, with the lead candidate IMCgp100 directed toward uveal melanoma treatment.

Immunocore's top competitors include Achilles Therapeutics, Autolus and LIfT Biosciences.

Yes, Immunocore is publicly traded on NASDAQ under the ticker symbol IMCR.

Immunocore has 13 investors. Key investors include Lilly, WuXi AppTec, BlackRock, General Atlantic, and Gates Foundation.

The valuation of Immunocore is $777.28M as of Jul 2015.

Immunocore operates through Immunocore Limited.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available